PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Recruiting now · Phase 1
Conditions studied: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
In brief
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab. The study will also be investigating how effective the combination is for a subgroup of breast cancer patients whose cancer expresses the androgen receptor (AR) but not the oestrogen (hormone) or HER2 receptors. Palbociclib is a drug used in routine care for hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer. It is possible that the combination of palbociclib and avelumab will be a more effective cancer treatment than each drug separately, but this is unknown and this study is needed to establish the best dosage and schedule of each drug as well as how effective the combination is.
Key facts
- Study ID
- NCT04360941
- Run by
- Royal Marsden NHS Foundation Trust
- People needed
- 45
- Starts
- 2020-08-11
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Weston Park Hospital — Sheffield, United Kingdom (enrolling)
- Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust — Cambridge, United Kingdom (enrolling)
- Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom (enrolling)
- Hope Clinical Trials Cancer Centre — Leicester, United Kingdom (enrolling)
- Barts Cancer Institute — London, United Kingdom (enrolling)
- Royal Marsden NHS Foundation Trust — London, United Kingdom (enrolling)
- University College London Hospitals NHS Foundation Trust — London, United Kingdom (enrolling)
- The Christie NHS Foundation Trust — Manchester, Greater Manchester, United Kingdom (enrolling)
- Nottingham University Hospital — Nottingham, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.